🟢 Telix Pharmaceuticals is trading 6.54% up today after announcing its proposed US$1.65 billion ITM deal

Telix Pharmaceuticals is trading 6.54% higher at A$16.79 after announcing its proposed US$1.65 billion acquisition of Germany’s ITM Isotope Technologies Munich. - Reuters said the deal would strengthen Telix’s radiopharmaceutical ambitions; ITM shareholders are expected to receive about US$1.25 billion in Telix shares. - Up to US$700 million in contingent payments depend on regulatory approvals and ITM-11 sales milestones. - After an 11.71% decline on September 21, shares rebounded 6.54%; dilution and execution risks remain.